MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial For Its Pediatric Asthma Product Candidate
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that in a pharmacokinetic clinical trial Unit Dose Budesonide (UDB) demonstrated lower systemic drug exposure when compared to the currently marketed conventional nebulized budesonide. UDB is MAP Pharmaceuticals’ proprietary nebulized formulation of budesonide, currently in Phase 3 clinical development, for the potential treatment of pediatric asthma. UDB is designed […]
How To Prevent From Asthma Attacks?
“A severe respiratory infection in infancy greatly increases the risk of developing asthma,” says the study’s lead author Mitchell Grayson, M.D., assistant professor of medicine in the Division of Allergy and Immunology. “Less than one in 30 people who don’t suffer a severe respiratory infection as a baby develop asthma, but of those who do […]
